Extra binding region induced by non-zinc chelating inhibitors into the S 1 subsite of matrix metalloproteinase 8 (MMP-8)

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 1040-1049

  Pochetti, Giorgio ^a   Montanari, Roberta ^a   Gege, Christian ^b,f   Chevrier, Carine ^b   Taveras, Arthur G ^c,e   Mazza, Fernando ^d  

^a CNR   (Italy)

^b Alantos Pharmaceuticals AG   (Germany)

^c Alantos Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e BIOGEN   (United States)

^f ASCENDIS PHARMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; ZINC; ZINC ION;

ARTICLE; CATALYST; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE;

BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MATRIX METALLOPROTEINASE 8; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 64349106309     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801166j     Document Type: Article

References (56)

1. Sternlicht, M. D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17, 463-516.
2. Shapiro, S. D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 1998, 10, 602-608.
3. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
4. Overall, C. M.; López-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672.
5. Holleran, W. M.; Galardy, R. E.; Gao, W. N.; Levy, D.; Tang, P. C.; Elias, P. M. Matrix metalloproteinase inhibitors reduce phorbol ester- induced cutaneous inflammation and hyperplasia. Arch. Dermatol. Res. 1997, 289, 138-144.
6. Hewson, A. K.; Smith, T.; Leonard, J. P.; Cuzner, M. L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 1995, 44, 345-349.
7. Chandler, S.; Coates, R.; Gearing, A.; Lury, J.; Wells, G.; Bone, E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 1995, 201, 223-226.
8. Lohmander, L. S.; Hoerrner, L. A.; Lark, M. W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 1993, 36, 181-189.
9. Ahrens, D.; Koch, A. E.; Pope, R. M.; Stein-Picarella, M.; Niedbala, M. J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 1996, 39, 1576-1587.
10. Blaser, J.; Triebel, S.; Maasjosthusmann, U.; Romisch, J.; Krahl- Mateblowski, U.; Freudenberg, W.; Fricke, R.; Tschesche, H. Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis. Clin. Chim. Acta 1996, 244, 17-33.
11. Ohishi, K.; Fujita, N.; Morinaga, Y.; Tsuruo, T. H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption. Clin. Exp. Metastasis 1995, 13, 287-295.
12. Witty, J. P.; Foster, S. A.; Stricklin, G. P.; Matrisian, L. M.; Stern, P. H. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B. J. Bone Miner. Res. 1996, 11, 72-78.
13. Peress, N.; Perillo, E.; Zucker, S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54, 16-22.
14. Chang, C.; Werb, Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell. Biol. 2001, 11, S37-S43.
15. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metallopro-teinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2392.
16. Puerta, D. T.; Cohen, S. M. A bioinorganic perspective on matrix metalloproteinase inhibition. Curr. Top. Med. Chem. 2004, 4, 1551-1573.
17. Matter, H.; Schudok, M. Recent advances in the design of matrix metalloprotease inhibitors. Curr. Opin. Drug Discovery Dev. 2004, 7, 513-535.
18. Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 2007, 13, 333-346.
19. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. 2004, 11, 2911-2977.
20. Rao, B. G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 2005, 11, 295-322.
21. Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
22. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995, 34, 14012-14020.
23. Muri, E. M.; Nieto, M. J.; Sindelar, R. D.; Williamson, J. S. Hydroxamic acids as pharmacological agents. Curr. Med. Chem. 2002, 9, 1631-1653.
24. Levin, J. I. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Curr. Top. Med. Chem. 2004, 4, 1289-1310.
25. Freskos, J. N.; McDonald, J. J.; Mischke, B. V.; Mullins, P. B.; Shieh, H. S.; Stegeman, R. A.; Stevens, A. M. Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1757-1760.
26. Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.; Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.; Sugita, K.; Ohtani, M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 1998, 41, 640-649.
27. Hodgson, J. Remodeling MMPIs. Biotechnology (N.Y.) 1995, 13, 554-557.
28. Puerta, D. T.; Lewis, J. A.; Cohen, S. M. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J. Am. Chem. Soc. 2004, 126, 8388-8389.
29. Puerta, D. T.; Mongan, J.; Tran, B. L.; McCammon, J. A.; Cohen, S. M. Potent, selective pyrone-based inhibitors of stromelysin-1. J. Am. Chem. Soc. 2005, 127, 14148-14149.
30. Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. A new role for old ligands: discerning chelators for zinc metalloproteinases. J. Am. Chem. Soc. 2006, 128, 3156-3157.
31. Li, X.; Li, Y.; Xu, W. Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential antitumor agents. Bioorg. Med. Chem. 2006, 14, 1287-1293.
32. Zhang, L.; Zhang, J.; Fang, H.; Wang, Q.; Xu, W. Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors. Bioorg. Med. Chem. 2006, 14, 8286-8294.
33. Campestre, C.; Agamennone, M.; Tortorella, P.; Preziuso, S.; Biasone, A.; Gavuzzo, E.; Pochetti, G.; Mazza, F.; Hiller, O.; Tschesche, H.; Consalvi, V.; Gallina, C. N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8. Bioorg. Med. Chem. Lett. 2006, 16, 20-24.
34. Mannino, C.; Nievo, M.; Machetti, F.; Papakyriakou, A.; Calderone, V.; Fragai, M.; Guarna, A. Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors. Bioorg. Med. Chem. 2006, 14, 7392-7403.
35. Nuti, E.; Tuccinardi, T.; Rossello, A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des. 2007, 13, 2087-2100.
36. Pirard, P. Insight into the structural determinants for selective inhibition of metalloproteinases. Drug Discovery Today 2007, 12, 640-646.
37. Georgiadis, D.; Yiotakis, A. Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg. Med. Chem. 2008, 16, 8781-8794.
38. Chen, J. M.; Nelson, F. C.; Levin, J. I.; Mobilio, D.; Moy, F. J.; Nilakantan, R.; Zask, A.; Powers, R. Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J. Am. Chem. Soc. 2000, 122, 9648-9654.
39. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 2005, 12, 181-189.
40. Morales, R.; Perrier, S.; Florent, J. M.; Beltra, J.; Dufour, S.; De Mendez, I.; Manceau, P.; Tertre, A.; Moreau, F.; Compere, D.; Dublanchet, A. C.; O'Gara, M. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J. Mol. Biol. 2004, 341, 1063-1076.
41. Johnson, A. R.; Pavlovsky, A. G.; Ortwine, D. F.; Prior, F.; Man, C. F.; Bornemeier, D. A.; Banotai, C. A.; Mueller, W. T.; McConnell, P.; Yan, C.; Baragi, V.; Lesch, C.; Roark, W. H.; Wilson, M.; Datta, K.; Guzman, R.; Han, H. K.; Dyer, R. D. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J. Biol. Chem. 2007, 282, 27781-27791.
42. Li, J. J.; Nahra, J.; Johnson, A. R.; Bunker, A.; O'Brien, P.; Yue, W. S.; Ortwine, D. F.; Man, C. F.; Baragi, V.; Kilgore, K.; Dyer, R. D.; Han, H. K. Quinazolinones and pyrido[3,4-d]pyrimidin-4- ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J. Med. Chem. 2008, 51, 835-841.
43. Overall, C. M.; Kleifeld, O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227-239.
44. Van Lint, P.; Wielockx, B.; Puimège, L.; Noël, A.; López-Otin, C.; Libert, C. Resistance of collagenase-2 (matrix metalloproteinase-8)- deficient mice to TNF-induced lethal hepatitis. J. Immunol. 2005, 175, 7642-7649.
45. Folgueras, A. R.; Fueyo, A.; Garcia-Suárez, O.; Cox, J.; Astudillo, A.; Tortorella, P.; Campestre, C.; Gutiérrez-Fernández, A.; Fanjul- Fernández, M.; Pennington, C. J.; Edwards, D. R.; Overall, C. M.; López-Otin, C. Collagenase-2 deficiency or inhibition impair experimental autoimmune encephalomyelitis in mice. J. Biol. Chem. 2008, 283, 9465-9474.
46. Van Lint, P.; Libert, C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 2006, 17, 217-223.
47. Gege, C.; Cevrier, C.; Schneider, M.; Bluhm, H.; Hochgürtel, M.; Deng, H.; Gallagher, B.; Sucholeiki, I.; Taveras, A. G. Heterotri- cyclic metalloprotease inhibitors. PCT Int. Appl. WO2008063667, 2008.
48. Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Maletta, M.; Yeo, K. J. Snapshots of the reaction mechanism of matrix metalloprotein- ases. Angew. Chem., Int. Ed. 2006, 45, 7952-7955.
49. Teague, S. J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discovery 2003, 2, 527-541.
50. Steeneck, C.; Gege, C.; Richter, F.; Hochgurtel, M.; Feuerstein, T.; Bluhm, H.; Sucholeiki, I.; Boer, J.; Wu, X.; Schneider, M.; Nolte, B.; Gallagher, B.; van Veldhuizen, J.; Deng, H.; Essers, M.; Kroth, H.; Kiely, A.; Powers, T.; Taveras, A. G. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors. PCT Int. Appl. WO2006128184, 2006.
51. Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloprotein- ases. FEBS Lett. 1992, 296, 263-266.
52. Schnierer, S.; Kleine, T.; Gote, T.; Hillemann, A.; Knauper, V.; Tschesche, H. The recombinant catalytic domain of human neutrophil collagenase lacks type I collagen substrate specificity. Biochem. Biophys. Res. Commun. 1993, 191, 319-326.
53. Leslie, A. G. W. Joint CCP4 and ESF-EACMB Newsletters on Protein Crystallography; SERC Daresbury Laboratory: Warrington, UK, 1992;Vol. 26.
54. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr., Sect. A: Found. Crystallogr. 1994, 50, 157-163.
55. Gavuzzo, E.; Pochetti, G.; Mazza, F.; Gallina, C.; Gorini, B.; D'Alessio, S.; Pieper, M.; Tschesche, H.; Tucker, P. A. Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design. J. Med. Chem. 2000, 43, 3377-3385.
56. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: a new software suite for macromo-lecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54 (Pt 5), 905-921.